Fenghua Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fenghua Liu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Zhaoyang Yu
Reproductive Medicine Center, The First Affiliated Hospital of Jinan University
3 shared publications- Huimei Wu
Guangxi Reproductive Medical Center, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
2 shared publications Mujun Li
Reproductive Medicine Center, The First Affiliated Hospital of Guangxi Medical University
2 shared publications- Ben Zhong Tang
The Chinese University of Hong Kong
1 shared publication - Chang Liu
Reproductive Medicine Center,Guangdong Women and Children Hospital, Guangzhou, China
1 shared publication Feiwen Li
Guangxi Reproductive Medical Center, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1857647
Integrated network toxicology and multi-omics profiling reveal cell cycle, DNA damage repair, and metabolic alterations in cyclophosphamide-induced premature ovarian insufficiency
Background: Cyclophosphamide (CTX)-induced chemotherapy injury is a leading iatrogenic cause of premature ovarian insufficiency (POI) and a major barrier to fertility preservation. Yet the systems-level mechanisms underlying its reproductive toxicity remain poorly defined. Methods: An integrated network toxicology framework incorporating machine learning and Mendelian randomization (MR) was applied to identify candidate targets, evaluate genetic associations, and establish a predictive model. Ovarian transcriptomic and metabolomic profiling, together with in vivo validation, were subsequently performed in a CTX-induced POI rat model. Single-cell-based in silico perturbation analysis was further conducted to investigate the potential cellular functions and mechanisms of key candidate targets in POI. Results: Integrated bioinformatic analyses and machine learning prioritized six candidate targets associated with CTX-induced ovarian injury, with PLS regression consistently identified as the optimal predictive model. SHAP analysis revealed CXCL1 and COL4A4 as the major contributors to model prediction. MR supported genetic associations between genetically predicted CXCL1/COL4A4 expression and POI risk. Immunohistochemical validation confirmed protein expression patterns consistent with transcriptomic findings. Multi-omics profiling revealed a convergent ovarian injury signature characterized by impaired cell-cycle regulation (G2/M checkpoint), defective DNA damage repair and mitotic function (mitotic spindle), enhanced apoptotic signaling, and coordinated suppression of folate metabolism, ubiquinone biosynthesis, and cytochrome P450-mediated drug metabolism pathways. Single-cell-based in silico perturbation analysis further suggested that CXCL1 and COL4A4 may contribute to ovarian dysfunction through regulation of inflammatory responses and extracellular matrix remodeling. Conclusion: This study shows that CTX-induced ovarian injury is accompanied by coordinated alterations in immune-inflammatory signaling, cell-cycle and DNA damage responses, and metabolic homeostasis. CXCL1 and COL4A4 were prioritized as candidate biomarkers associated with POI risk, providing potential targets for further mechanistic investigation and fertility-preserving interventions.
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1857647
Open AccessIntegrated network toxicology and multi-omics profiling reveal cell cycle, DNA damage repair, and metabolic alterations in cyclophosphamide-induced premature ovarian insufficiency
Background: Cyclophosphamide (CTX)-induced chemotherapy injury is a leading iatrogenic cause of premature ovarian insufficiency (POI) and a major barrier to fertility preservation. Yet the systems-level mechanisms underlying its reproductive toxicity remain poorly defined. Methods: An integrated network toxicology framework incorporating machine learning and Mendelian randomization (MR) was applied to identify candidate targets, evaluate genetic associations, and establish a predictive model. Ovarian transcriptomic and metabolomic profiling, together with in vivo validation, were subsequently performed in a CTX-induced POI rat model. Single-cell-based in silico perturbation analysis was further conducted to investigate the potential cellular functions and mechanisms of key candidate targets in POI. Results: Integrated bioinformatic analyses and machine learning prioritized six candidate targets associated with CTX-induced ovarian injury, with PLS regression consistently identified as the optimal predictive model. SHAP analysis revealed CXCL1 and COL4A4 as the major contributors to model prediction. MR supported genetic associations between genetically predicted CXCL1/COL4A4 expression and POI risk. Immunohistochemical validation confirmed protein expression patterns consistent with transcriptomic findings. Multi-omics profiling revealed a convergent ovarian injury signature characterized by impaired cell-cycle regulation (G2/M checkpoint), defective DNA damage repair and mitotic function (mitotic spindle), enhanced apoptotic signaling, and coordinated suppression of folate metabolism, ubiquinone biosynthesis, and cytochrome P450-mediated drug metabolism pathways. Single-cell-based in silico perturbation analysis further suggested that CXCL1 and COL4A4 may contribute to ovarian dysfunction through regulation of inflammatory responses and extracellular matrix remodeling. Conclusion: This study shows that CTX-induced ovarian injury is accompanied by coordinated alterations in immune-inflammatory signaling, cell-cycle and DNA damage responses, and metabolic homeostasis. CXCL1 and COL4A4 were prioritized as candidate biomarkers associated with POI risk, providing potential targets for further mechanistic investigation and fertility-preserving interventions.
- Open Access
- 5 June 2026
- Published by Springer Nature in Research Square
Multimodal AIE-mediated heat-responsive gas biomimetic controlled-release platform for mild photothermal real-time diagnosis and therapy
Mild-temperature photothermal therapy (mPTT) can mitigate thermal damage to adjacent tissues while still inducing cancer cell death in tumor therapy. However, mild heating induces tumor thermotolerance that blunts efficacy. Addressing this issue, we developed an NIR-II aggregation-induced emission (AIE) biomimetic gas-delivery nanosystem for trimodal imaging-guided mPTT on a CT26 colon cancer model. Py (an NIR-II AIE photothermal/fluorescent agent) and BNN6 (a heat-responsive NO donor) were encapsulated in (lactic-co-glycolic acid) (PLGA) nanoparticles which was further camouflaged with CT26 cell membranes (BP@M) to enable homologous recognition, prolonged retention, and improved tumor infiltration. Under NIR irradiation, Py provided mild hyperthermia and simultaneously activated BNN6 for irradiation-gated, on-demand NO release. The locally generated NO disrupted mitochondrial function, depleted ATP, attenuated HSP90-associated thermotolerance, and promoted caspase-3-mediated apoptosis. In vivo , “BP@M + NIR” achieved marked tumor suppression with minimal systemic toxicity, outperforming mPTT alone. This platform offers an effective and controllable theranostic strategy for cancer treatment.
- 5 June 2026
- Published by Springer Nature in Research Square
Open AccessMultimodal AIE-mediated heat-responsive gas biomimetic controlled-release platform for mild photothermal real-time diagnosis and therapy
Mild-temperature photothermal therapy (mPTT) can mitigate thermal damage to adjacent tissues while still inducing cancer cell death in tumor therapy. However, mild heating induces tumor thermotolerance that blunts efficacy. Addressing this issue, we developed an NIR-II aggregation-induced emission (AIE) biomimetic gas-delivery nanosystem for trimodal imaging-guided mPTT on a CT26 colon cancer model. Py (an NIR-II AIE photothermal/fluorescent agent) and BNN6 (a heat-responsive NO donor) were encapsulated in (lactic-co-glycolic acid) (PLGA) nanoparticles which was further camouflaged with CT26 cell membranes (BP@M) to enable homologous recognition, prolonged retention, and improved tumor infiltration. Under NIR irradiation, Py provided mild hyperthermia and simultaneously activated BNN6 for irradiation-gated, on-demand NO release. The locally generated NO disrupted mitochondrial function, depleted ATP, attenuated HSP90-associated thermotolerance, and promoted caspase-3-mediated apoptosis. In vivo , “BP@M + NIR” achieved marked tumor suppression with minimal systemic toxicity, outperforming mPTT alone. This platform offers an effective and controllable theranostic strategy for cancer treatment.
- Open Access
- 5 February 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 9404-9426
Multi-target modulation of the homologous recombination pathway by resveratrol promotes DNA damage repair in POI: integrated network pharmacology, molecular dynamics simulation, and experimental validation
Background: Premature ovarian insufficiency (POI) is characterized by gonadotropin elevation, estrogen deficiency, and follicular loss. Resveratrol (RSV), a natural polyphenol with antioxidant and anti-aging properties, shows therapeutic promise for POI, but its molecular targets and mechanisms remain unclear. Methods: Network pharmacology analysis was used to identify overlapping targets of RSV and POI, followed by Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, protein–protein interaction (PPI) network construction, and hub gene screening. Molecular docking and dynamics simulations were performed to characterize the affinity and binding stability. In vivo , a cyclophosphamide-induced POI rat model was established to evaluate the protective effects of RSV on ovarian morphology and hormone levels. In vitro , a 4-hydroperoxycyclophosphamide-induced granulosa cell model was used to assess DNA damage and homologous recombination (HR) activity through TUNEL staining, Western blotting, and nuclear foci analysis, with RAD51 inhibition applied to verify pathway dependence. Results: About 609 overlapping genes between RSV- and POI-related targets were identified. GO and KEGG enrichment analyses revealed significant involvement in reproductive system development, DNA repair complex, and cellular senescence. PPI and topological analysis identified three core genes – ATM, BRCA1, and RAD51 – significantly enriched in the HR pathway. Molecular docking and dynamic simulations indicate that RSV has a strong affinity and stable binding mode with these three targets. In vivo , RSV ameliorated cyclophosphamide-induced ovarian injury, increasing serum anti-Müllerian hormone levels and secondary follicle counts. Mechanistically, in the POI cell model, RSV upregulated RAD51 and downregulated γH2AX expression, thereby promoting HR pathway activation and DNA double-strand break repair. The protective effect of RSV was abolished by the RAD51 inhibitor RI-1. Immunofluorescence foci analysis further verified that RSV enhanced the recruitment of RAD51 to DNA damage sites and reduced nuclear γH2AX accumulation. Conclusion: This study provides structural and experimental evidence for the target selection, structural optimization, and molecular mechanism of RSV in the treatment of POI.
- 5 February 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 9404-9426
Open AccessMulti-target modulation of the homologous recombination pathway by resveratrol promotes DNA damage repair in POI: integrated network pharmacology, molecular dynamics simulation, and experimental validation
Background: Premature ovarian insufficiency (POI) is characterized by gonadotropin elevation, estrogen deficiency, and follicular loss. Resveratrol (RSV), a natural polyphenol with antioxidant and anti-aging properties, shows therapeutic promise for POI, but its molecular targets and mechanisms remain unclear. Methods: Network pharmacology analysis was used to identify overlapping targets of RSV and POI, followed by Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, protein–protein interaction (PPI) network construction, and hub gene screening. Molecular docking and dynamics simulations were performed to characterize the affinity and binding stability. In vivo , a cyclophosphamide-induced POI rat model was established to evaluate the protective effects of RSV on ovarian morphology and hormone levels. In vitro , a 4-hydroperoxycyclophosphamide-induced granulosa cell model was used to assess DNA damage and homologous recombination (HR) activity through TUNEL staining, Western blotting, and nuclear foci analysis, with RAD51 inhibition applied to verify pathway dependence. Results: About 609 overlapping genes between RSV- and POI-related targets were identified. GO and KEGG enrichment analyses revealed significant involvement in reproductive system development, DNA repair complex, and cellular senescence. PPI and topological analysis identified three core genes – ATM, BRCA1, and RAD51 – significantly enriched in the HR pathway. Molecular docking and dynamic simulations indicate that RSV has a strong affinity and stable binding mode with these three targets. In vivo , RSV ameliorated cyclophosphamide-induced ovarian injury, increasing serum anti-Müllerian hormone levels and secondary follicle counts. Mechanistically, in the POI cell model, RSV upregulated RAD51 and downregulated γH2AX expression, thereby promoting HR pathway activation and DNA double-strand break repair. The protective effect of RSV was abolished by the RAD51 inhibitor RI-1. Immunofluorescence foci analysis further verified that RSV enhanced the recruitment of RAD51 to DNA damage sites and reduced nuclear γH2AX accumulation. Conclusion: This study provides structural and experimental evidence for the target selection, structural optimization, and molecular mechanism of RSV in the treatment of POI.